Sandbox Reserved 1613

ABCG2 Transporter Protein

spinqualitylabelsall models Figure 1: ABCG2 6FFC Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image   Print3D Introduction The ABCG2 transporter protein is a notable transmembrane protein. It transports xenobiotic material out of cells in many tissues. ABCG2 belongs to the family of 48 transporter proteins called ATP-binding cassette transporters (ABC transporters). The ABC transporters differ from each other by their size structure, and ordering of domains. Ample evidence has shown a link between multi-drug resistance and the presence of ABC transporters in the plasma membrane of cells. This is important as multi-drug resistance is one of the major indicators of bad prognoses in cancer treatment. In fact, 19 of the 48 transporters of the ABC family have been shown to transport chemotherapeutic agents out of cells. In recent studies, with cryogenic electronic microscopy (Cryo EM), the unique two cavity substrate transport structure, inward facing nucleotide binding domain and condensed EL-3 structure of ABCG2 have been elucidated, among other features. These new discoveries have allowed for progress towards discovering the exact link between cancer and the ABC transporter family and have allowed for more effective drug treatment of cancer. This page will focus on the family of ABC transporters before delving into unique structural features of ABCG2 and finally describing the effects of this transporter on anti-cancer treatment. ABC Transporter Family In the 1990's, ABC binding cassette transporters became the subject of much discussion as many were found to have links to the inhibition of anti-cancer therapies. All 48 members of the family were studied and several structural aspects were found to be important to the characterization of transporters in this family. The first was the presence of two nucleotide binding domains (NBD) located in the cytoplasm of all cells which bound and hydrolyzed ATP, providing the necessary energy for transport of the substrate to occur. In all 7 subfamilies (A-G) of the ABC family, the NBD's are greatly conserved. Each transporter of this family is made unique by the structure and form of their specific transmembrane binding domain (TMD). Each of the 48 transporters have 2 transmembrane domains which work to recognize and transport the substrates across the plasma membrane and out of the cell. The residues in the TMD provide the transporters each with specific substrates which they can transport. They also allow for the coupling of transport with ATP hydrolysis to transport molecules regardless of the concentration gradient. Specific Members of the Family As previously mentioned, 19 of the 48 members of the transporter family are involved in chemotherapeutic removal from the cell. Of these, three, ABCB1, ABCG2 and ABCC1 were identified for further study and comparison of structure due to their function as multi-drug transporters. The differences in their structures provided valuable information for scientific research into their substrate binding processes. General Structure The ABCG2 protein is comprised of a homodimer which each have two specific domains: one spanning the cell membrane and one involved with nucleotide binding. Mechanism of Substrate Transport Figure 1: MZ29 bound to cavity 1 of ABCG2 (6ffc). Two MZ29 are shown in sticks and are colored by element. Hydrophobic interactions between the surface of cavity 1 and MZ29 are shown in green. Multidrug Transporter ABCG2 is a dimer that consists of two cavities seperated by a leucine plug. Cavity 1 is a binding pocket open to the cytoplasm and the inner leaflet of the plasma membrane. Its shape is suitable to bind flat, hydrophobic and polycyclic substrates. Many of its amino acids residues form hydrophobic interactions with the bound substrate, as shown in green in Figure 1. Cavity 2 is located above the leucine plug. It is empty until a magnesium ion and ATP are bound to ABCG2. Its inter- and intra-disulfides (yellow is inter- and intra-molecular disulfides, golden is intra-molecular only) promote the release of the substrate from the cavity into the extracellular space. One interesting feature of the NBD's is the fact that they remain in contact with one another even without a bound substrate. This makes the ABCG2 transporter unique and provides greater substrate specificity as the entrance to the transporter is not as globular as either ABCB1 or ABCC1. The entrance from the cytoplasm to the transporter is a hydrophobic membrane entrance lined by residues A397, V401, L405, L539, I543 and T547 in both monomers. Dimerization of ABCG2 was originally thought to be achieved with the help of the 406xxx410 structural motif in each of the two domains but Cryo-EM showed that the motifs were on opposite sides of the protein. Transmembrane Domains In the transmembrane domain is located the leucine plug that separates the first site of binding from the second site of binding for the substrate. Both domains are stabilized by several interactions both intermolecularly. The first and most prominent feature of the TMD is EL-3. This loop which extends out from the transmembrane domain has been shown to be involved in stabilization of the TMD's. A member of the same subfamily, ABCG5/ABCG8, was shown to have EL-3 helices that extended further into the extracellular space. This condensed helices is one of the defining features of ABCG2 transporter protein. The EL-3 of ABCG2 is stabilized by both intermolecular and intramolecular disulfide bonds at 592, 608 and between Cys 603 of each domain. Nucleotide Binding Domains These two domains contain the active site of this transporter protein. The interest in this protein is in its involvement with mutidrug resistant cancer cells. This involvement is due to its active site's promiscuity as many xenobiotics have been found to transported to the outside of the cell by this transporter. Function ABCG2 transports a variety of substrates, particularly flat, hydrophobic, and/or polycylic molecules. It is found in different biological membranes, such as the blood-brain barrier (BBB), blood-testis barrier, and the blood-placental barrier. It is thought to help protect those tissues and many others from cytotoxins. In addition to cytotoxin protection, ABCG2 secretes endogenous substrates in the adrenal gland, excretes toxins in the liver and kidneys, and regulates absorption of substrates. Relevance By utilizing certain binders (5D3), it is able to be stabilized for crystallographic imaging. This has allowed researchers in the past decade to make advances based upon the greater understanding of its structure. Using these advances, inhibitors have been found to stop effluxion by ABCG2. Completely inhibiting this function, however, has residual effects on the excretory system. One such effect is decreased uric acid excretion in both the kidneys and the gut, which causes hyperuricemia . This results in an increased risk of uric acid crystal build-up, known as tophi formation, which causes a type of arthritis known as gout . Balancing the inhibition of ABCG2 will determine how to lessen these effects while continuing to combat cancer resistivity. Disease One of the causes for multidrug resistant cancers is the excretion of cancer drugs out of the cell, thereby decreasing the effective intracellular concentration. ABCG2, also known as the breast cancer resistance protein (BCRP), effluxes multiple chemotherapeutic agents such as mitoxantrone and camptothecin analogies, making the cancerous breast cells resistant to chemotherapy. Competitive inhibitors, such as MZ29, that shut down ABCG2 to stop the efflux of cancer drugs in order to combat the resistivity of breast cancer. This family has been found as a prevalent piece of multi-drug resistant cancers and therefore became a popular target towards inhibition. Three generations of drugs were made in order to inhibit a similar protein from the same family, ABCC1 at its interior binding site including cyclosporine A (first generation), valspodar (second generation), and Elacridar (3rd generation). Importantly, cyclosporine A and Elacridar were found to inhibit both ABCC1 and ABCG2 and in one trial had success along with chemotherapy in the treatment of acute myeloid leukemia but because of either side effects or experimentation that was not able to be duplicated, this research was mostly shelved. The main issue in their failure to find a drug to inhibit this protein was the failure to develop a high-resolution structure of this protein with the technology available at the time of this drug development. In the mid 2010's, upgrades to cryo-electron microscopy and the use of 2 antigen binding fragments (5D3-Fab) allowed for high resolution images to finally be developed for ABCG2 transporter protein. With these recent discoveries, the understanding of this protein has greatly increased in the last several years.

Student Contributors

Shelby Skaggs, Samuel Sullivan, Jaelyn Voyles